BCN 303

BCN 303 (also referred to as B303) is a preclinical-stage monoclonal antibody being developed by BCN Biosciences for the treatment of solid tumors, specifically breast and colon cancer. The therapeutic is designed to target endothelial-derived gene products that are implicated in the progression and maintenance of these malignancies. BCN Biosciences, a biotechnology company specializing in oncology drug discovery, is currently advancing BCN 303 through definitive preclinical studies. The therapeutic approach focuses on modulating the tumor microenvironment by targeting specific gene products derived from endothelial cells, which play a critical role in tumor vascularization and growth.